Table 3.
Baseline patient characteristics and treatment outcomes stratified by study arms
| Baseline patient characteristic | Study vs historical control period | Study period only | ||||
|---|---|---|---|---|---|---|
| Historical control | Study | Chi-square p-value | Not enrolled in study | Enrolled in study | Chi-square p-value | |
| Baseline patient characteristics | ||||||
| Age, mean (SD) | 37.0 (14.7) | 35.7 (13.2) | 0.45 | 37.3 (12.5) | 34.1 (13.7) | 0.12 |
| Female (%) | 38 (34.5) | 69 (42.3) | 0.24 | 37 (46.8) | 32 (38.1) | 0.33 |
| HIV-positive (%) | 78 (70.9) | 114 (69.9) | 0.97 | 56 (70.9) | 58 (69.0) | 0.93 |
| On ART at start of treatment (%) | 40 (51.3) | 47 (41.2) | 0.22 | 30 (53.6) | 17 (29.3) | 0.01 |
| Previously treated* (%) | 18 (16.4) | 40 (24.5) | 0.14 | 15 (19.0) | 25 (29.8) | 0.16 |
| Smear-positive (%) | 35 (31.8) | 33 (20.2) | 0.04 | 14 (17.7) | 19 (22.6) | 0.60 |
| Treatment outcomes | ||||||
| Success (Cured/completed) | 50 (45.5) | 75 (46.0) | 0.16 | 45 (53.6) | 30 (38.0) | 0.27 |
| Died | 3 (2.7) | 4 (2.5) | 1 (1.2) | 3 (3.8) | ||
| Lost to follow-up | 9 (8.2) | 18 (11.0) | 8 (9.5) | 10 (12.7) | ||
| Transferred out | 26 (23.6) | 50 (30.7) | 24 (28.6) | 26 (32.9) | ||
| Not evaluated | 22 (20.0) | 16 (9.8) | 6 (7.1) | 10 (12.7) | ||
Abbreviations: ART Antiretroviral therapy, SD Standard deviation